S
VKTX icon

Sachetta’s Viking Therapeutics VKTX Stock Holding History

Sachetta’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.2K Hold
159
– – ﹤0.01% 593
2026
Q1 		$5.17K Sell
159
-20
-11% -$643 ﹤0.01% 647
2025
Q4 		$6.3K Buy
179
+20
+13% +$709 ﹤0.01% 487
2025
Q3 		$4.18K Hold
159
– – ﹤0.01% 650
2025
Q2 		$4.21K Buy
159
+141
+783% +$3.71K ﹤0.01% 629
2025
Q1 		$435 Buy
+18
New +$569 ﹤0.01% 1054
2024
Q4 		– Sell
-1
Closed -$64 – 1283
2024
Q3 		$64 Sell
1
-16
-94% -$939 ﹤0.01% 1200
2024
Q2 		$961 Buy
+17
New +$1.11K ﹤0.01% 1055

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Sachetta's VKTX Position: Q2 2026 in Review

Sachetta held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 159 shares worth $6.2K. The position accounts for ﹤0.01% of the portfolio, ranked #593.

Sachetta first reported a position in VKTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $6.3K in Q4 2025. 434 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Sachetta held 159 shares of Viking Therapeutics worth $6.2K as of Q2 2026.
  • Sachetta left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of Sachetta's portfolio in Q2 2026, its #593 holding.
  • Sachetta first reported a position in Viking Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Sachetta's Viking Therapeutics position peaked at $6.3K in Q4 2025.
  • 434 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Sachetta's 13F filing for Q2 2026, filed 15 Jul 2026.